Table 3 m6A-targeted anti-tumor treatment
From: Functions of N6-methyladenosine in cancer metabolism: from mechanism to targeted therapy
Cancer Type | m6A | Treatment | Reference |
|---|---|---|---|
Colorectal cancer | METTL3 | METTL3 knockout via lentiviral-based CRISPR gene editing system decreases HK2 and GLUT1 level and the reduces hexokinase activity to inhibit tumorigenesis. | [79] |
Liver cancer | METTL3 | The knockdown of METTL3 via shRNA attenuates PDK4 mRNA stability, inhibits glycolysis and exhibits anti-tumor effect. | [92] |
Cervical cancer | METTL3 | The knockdown of METTL3 via shRNA induces reduced lactate production and ATP level and suppresses tumorigenesis. | [75] |
Hepatocellular carcinoma | METTL5 | METTL5 depletion and siACSL4 reduce the levels of free fatty acids, triglycerides and intracellular lipid droplets and blocks tumor initiation. | [121] |
Colorectal cancer | KIAA1429 | KIAA1429 knockdown via shRNA represses tumor growth, which leads to reduced glucose uptake and lack of ATP production. | [80] |
Acute myeloid leukemia | IGF2BP2 | IGF2BP2 knockdown via shRNA and IGF2BP2 inhibition by CWI1-2 delay leukemogenesis and development. | [128] |
| Â | METTL16 | METTL16 knockdown via shRNA suppresses the expression of BCAT1 and BCAT2 in amino acid metabolism to inhibit tumorigenesis and development. | [129] |
Papillary thyroid cancer | FTO | FTO overexpression via lentiviruses containing complete FTO coding sequence reduces GLUT1, HK2 and LDHA levels, attenuates glycolysis and suppresses tumor growth. | [134] |
Clear cell renal cell carcinoma | FTO | FTO knockdown via shRNA reduces the levels of SLC1A5 and glutamine uptake to inhibit tumor growth. | [126] |
Gastric cancer | YTHDF1 | YTHDF1 depletion via siRNA encapsulated by sEV modulates immune responses and suppresses tumor development and metastasis. | [135] |